



OPEN ACCESS

EDITED BY

Yi-Hung Chen,
China Medical University, Taiwan

REVIEWED BY

Mostafa Shahien,
Cairo University, Egypt
Toshio Higashi,
Nagasaki University, Japan
MingCheng Huang,
China Medical University Hospital, Taiwan

*CORRESPONDENCE

Guangyao Li
✉ 425293675@qq.com
Min Li
✉ doctorlimin@gzucm.edu.cn
Jia Xiong
✉ 12366104@qq.com

RECEIVED 03 July 2023

ACCEPTED 21 December 2023

PUBLISHED 12 January 2024

CITATION

Huang Y, Tan T, Liu L, Yan Z, Deng Y, Li G,
Li M and Xiong J (2024) Exercise for reducing
chemotherapy-induced peripheral
neuropathy: a systematic review and meta-
analysis of randomized controlled trials.
Front. Neurol. 14:1252259.
doi: 10.3389/fneur.2023.1252259

COPYRIGHT

© 2024 Huang, Tan, Liu, Yan, Deng, Li, Li and
Xiong. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials

Yingjie Huang¹, Tian Tan², Lu Liu³, Zijian Yan³, Yuexia Deng⁴,
Guangyao Li^{5*}, Min Li^{2*} and Jia Xiong^{6*}

¹Guangzhou University of Chinese Medicine, Guangzhou, China, ²Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China, ³The First Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China, ⁴Southern Theater General Hospital, Guangzhou, China, ⁵Department of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ⁶Nanchang Hongdu Hospital of Traditional Chinese Medicine, Nanchang, Jiangxi Province, China

Background: More than half of cancer patients develop severe chemotherapy-induced peripheral neuropathy (CIPN), resulting in low quality of life, negative effects on function, and challenges in treatment compliance. Most recent studies have shown that exercise therapy has a positive impact on reducing CIPN symptoms and can also improve quality of life, balance, and activity levels. The aim of this meta-analysis was to evaluate the effect of exercise therapy on the efficacy of CIPN.

Methods: Computerized search of Embase, Web of Science, CNKI, Wan Fang Data, VIP, CBM for RCTs on exercise therapy for CIPN from database creation to November 2022, without language restriction. The Cochrane Handbook 5.3 risk of bias assessment tool was used to evaluate the quality of the included studies. Then Revman 5.3 software was used to evaluate the quality of the included studies. The heterogeneity of the research results is tested by I^2 , continuous variables were presented as weighted mean difference or standard mean difference, and confidence intervals were set at 95%. Stata15.0 was utilized to conduct a meta-analysis.

Results: A total of 15 RCTs with 1,124 patients were included. Meta-analysis showed that the test group was superior to the control group in terms of total symptom score (SMD: -0.62 ; 95% CI: $-0.99, -0.24$), numbness, tingling, quality of life score (total score, physical, function), pain, balance, and neurotoxicity function assessment (FACT/GOG-NTX) questionnaire ($p < 0.05$).

Limitations: The duration and frequency of treatment are different every week, which may have some impact on the results.

Conclusion: Exercise therapy can be effective in treating CIPN by improving symptom score (total symptom score, numbness, tingling), quality of life score (total score, physical function), pain, balance, and FACT/GOG-NTX questionnaires. It still needs to be refined and validated by more high-quality, multicenter, large-sample RCTs in the future.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022373131, identifier: CRD42022373131.

KEYWORDS

exercise therapy, chemotherapy-induced peripheral neuropathy, CIPN, efficacy, meta-analysis

1 Introduction

Cancer is one of the leading causes of death worldwide (1, 2). According to relevant research statistics, by 2040, the annual number of new cancer cases is expected to rise to 29.5 million, and the number of cancer-related deaths will increase to 16.4 million [Global Cancer Observatory (Fig. iarc.fr)]. Chemotherapy is the most common and effective method for treating cancer. However, more than half all-cause cancer patients have developed severe peripheral neuropathies (3) during chemotherapy treatment which called chemotherapy-induced peripheral neuropathy (CIPN). CIPN is caused by multiple chemotherapeutic drugs that can damage sensory, motor, autonomic, or cranial nerves and typically manifest as numbness, loss of proprioception sense, tingling, burning painpins, and hyperalgesia present (4). The insufficient awareness of its pathogenesis, appropriate dosage and benefits of rehabilitation in reducing the severity of CIPN, leads to low patients' quality of life, negative impacts on functional outcomes and challenges of treatment compliance (5).

The neurotoxic alterations in intracellular organelles, membrane receptors and ion channels, induced by chemotherapeutic agents will cause alterations of the intracellular homeostasis, signaling and neurotransmission, finally leading to the occurrence of CIPN (6). Unfortunately, we have not found treatments for CIPN, and the current first-line drugs used to treat CIPN shows mild or unsatisfactory therapeutic efficacy. Symptomatic treatment gabapentin, nortriptyline and amitriptyline which use to treat neuropathic pain show only modest or no benefits in some randomized, double-blinded, placebo controlled crossover study on CIPN (7–9). Only duloxetine suggested definite effect to relief neuropathic pain in CIPN in recent studies (10). Cumulated evidence indicates that ion channels plays a critical role in the pathology of painful CIPN, therefore ion channel blocker may be a promising candidate for concomitant use against CIPN, but there still remains few convincing evidence supporting its efficacy (11).

According to ASCO guideline (2), in the context of a clinical trial, non-pharmacological options for patients who have completed neurotoxic chemotherapy include exercise, acupuncture, and scrambler therapy, but larger sample-sized conclusive studies are needed to confirm efficacy and clarify risks. Given low risk of harm, these non-pharmacological options also received weak recommendations in The European Society of Medical Oncology guidelines (12).

Exercise therapy is a simple and cost-effective rehabilitation method. Exercise therapy is an intervention to improve CIPN symptoms through proper stretching followed by aerobic training and/or strength training of major muscle groups. Its types broadly include strength training, aerobic exercise, stretching, sensory training (13). Most recent studies have shown that exercise therapy has a positive impact on decreasing peripheral neuropathy symptoms and also can improve quality of life, balance, and activity levels (14). Analyzing its mechanism, exercise can up regulate the levels of multiple protective Neurotrophin, including glial Neurotrophin,

Brain-derived neurotrophic factor and Insulin-like growth factor, in order to promote the growth, survival and differentiation of mature and developing neurons, change the vascular function and metabolic activity of peripheral nerves, reduce inflammation and alleviate CIPN symptoms (15). Currently, multicenter, large-sample randomized controlled trials remain lacking, and there is no sufficient evidence-based evidence of exercise on CIPN symptoms in cancer patients. Therefore, this study demonstrated through systematic review and meta-analysis that exercise therapy treats CIPN by improving symptom scores, quality of life scores, pain, balance, FACT/GOG-NTX questionnaire, and provide evidence-based medical conclusion to improve this clinical problem.

2 Methods

We have registered this study with the PROSPERO international prospective register of systematic reviews (CRD42022373131). This study was conducted as claimed by the recommendations of the Cochrane and follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (16).

2.1 Inclusion criteria

The population-intervention Comparators-Outcomes-Study design (PICOS) framework was used as the eligibility criteria for the review as follows.

2.1.1 Selection of studies

All randomized controlled trials (RCT) investigating exercise therapy for CIPN without language restriction.

2.1.2 Selection of participants

The study subjects were patients clinically diagnosed with peripheral neuropathy caused by cancer chemotherapy, and all chemotherapy patients had symptoms of peripheral neuropathy, which did not limit the types of cancer and chemotherapeutic drugs.

2.1.3 Types of interventions

All of the patients received chemotherapy and had CIPN. The experimental group was treated with exercise therapy, including stretching exercise, strength training, yoga, balance exercise, sensory exercise, aerobic exercise. No restriction on the type of exercise therapy, one or more exercises can be used. The control group was treated with usual care or health education. Studies that did not meet the above inclusion criteria were excluded. In addition, the following exclusion criteria were used: ① not randomized controlled trial; ② peripheral neuropathy caused by other diseases in patients; ③ patients had recovered from CIPN after the end of chemotherapy; ④ CIPN patients received duloxetine; ⑤ studies without original data or

incomplete study data; © studies with interventions that did not meet the inclusion criteria.

2.2 Outcome measures

Through the review of clinical trials published in major databases and academic journals to evaluate CIPN, We found that the primary outcome was symptom score (total symptom score, numbness, tingling), the secondary outcome includes quality of life score (total score, physical, functional, social, emotional, neurotoxicity), pain, balance, and functional assessment of neurotoxicity (FACT/GOG-NTX) questionnaire.

2.3 Database search

PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wan Fang Data Knowledge Service Platform (Wan Fang Data), China Science and Technology Journal Database (VIP), Chinese biomedical literature database (CBM) were searched by computer from database establishment to November 2022. The search strategy used the following keywords: “chemotherapy-induced peripheral neurotoxicity,” “CIPN,” “exercise therapy,” “Exercise,” and “Rehabilitation.” Taking PubMed as an example, search terms and strategies were as follows: [(chemotherapy-induced neurotoxicity) OR (chemotherapy-induced peripheral neuropathy) OR (CIPN)] AND [(exercise therapy) OR (Exercise Therapies)] OR (Therapies, Exercise) OR (Rehabilitation Exercise) OR (Exercise, Rehabilitation) OR (Rehabilitation Exercise).

2.4 Literature screening and data extraction

Two investigators (YH, TT) independently performed literature screening in strict accordance with the inclusion and exclusion criteria, and the retrieved articles were managed and identified using Note Express software. Excel software was used to establish literature information extraction data, including study type, number of cases, age, cancer type, chemotherapeutic drugs used, disease duration, intervention treatment duration, and outcome measures. Finally, findings were cross-checked and disputes resolved by discussion or consultation with third parties.

In cases where primary data is unavailable or presented graphically in studies, attempts will be made to contact the respective authors to request the primary data, and the data in the figures will be extracted using GetData Graph Digitizer 2.26.

2.5 Quality assessment

The Cochrane Handbook 5.3 risk of bias assessment tool was used to evaluate the quality of the included studies, while Revman 5.3 was used to evaluate the methodological quality of the articles. These include: (1) random sequence generation; (2) allocation concealment; (3) blinding of subjects and study personnel; (4) blinding of results evaluators; (5) completeness of outcome data; (6) selective reporting of study results; and (7) other biases. The evaluation results were expressed as “low risk of bias,” “unclear risk of bias” and “high risk of bias.”

2.6 Certainty assessment

GDT software (17) was used to assess the certainty of evidence according to the GRADE guidelines (gradeworkinggroup.org) for primary outcomes based on areas of study design, risk of bias, inconsistency, indirectness, imprecision, and other considerations, such as publication bias, effect size, and potential confounding. And the quality of the final evidence was classified as high, moderate, low and very low (18, 19).

2.7 Statistical analysis

Stata 15.0 software was used to perform the meta-analysis. Continuous variables were analyzed by the inverse variance approach, with the weighted mean difference (WMD) used as the effect indicator. When the absolute difference of continuous variables is large or the unit is uneven, the standardized mean difference (SMD) was used as the effect indicator. And the confidence intervals (CI) set at 95%. Heterogeneity of study results was tested using I^2 . Results data from the fixed effects model (FE) were selected for analysis if $I^2 \leq 50\%$; results data from the random effects model (RE) were selected for combined analysis if $I^2 > 50\%$. Subgroup meta-analysis and sensitivity analysis was used to analyze the source of heterogeneity and assess the stability of meta-analysis results. Funnel plots were used to analyze the publication bias of the studies.

3 Results

3.1 Search results

According to the search strategy, 503 studies were retrieved. After exclusion of 197 duplicate studies, abstracts and titles of 306 studies were carefully read. After exclusion of titles and abstracts, 70 studies were read in full. After full-text evaluation, 55 studies were excluded for the following reasons: not RCTs ($n = 23$), lack of data ($n = 19$), and Inappropriate test design ($n = 13$). Eventually, 15 studies (14, 20–33) and 1,124 patients were included in this Meta-analysis. The studies included in this meta-analysis were multicenter, mainly from the United States, Germany, and China. 13 studies in English and 2 studies in Chinese. Exercise therapy includes stretching, balance, yoga, sensory, strength training, aerobic exercise. The duration of each exercise is 15–60 min, mainly focusing on 30 min, 60 min. The frequency of exercise is mainly 1 time/day, 2 times/week, 3 times/week, 5–7 times/week. The intervention time was 2–36 weeks, mainly 6 weeks and 12 weeks. The patient’s cancer types were Breast/Lymphoma/Colon/Lung/Hematological malignancy/ Gastrointestinal / Ovarian / Cervical cancer, and the chemotherapeutic drugs used were mainly Taxane and Platinum (Table 1). The PRISMA flowchart shows this process (Figure 1).


3.2 Risk of bias assessment

The quality of the included studies was moderate. Thirteen studies involved two-arm design (14, 20–26, 28, 30–33), two studies involved three-arm design (28, 29). Twelve studies reported the correct method

TABLE 1 The basic characteristics of the included studies.

Trail	Country	Sample size (T/C)	Age(y), Mean \pm SD or Median (Range)		Duration/W		T	C	Main outcomes	Frequency	Follow-up time/week	Cancer	Chemotherapy
			T	C	T	C							
Şimşek et al. (29)	Turkey	30,30/30	>18y	>8y	NA	NA	Stretching exercise+balance exercise	Chemotherapy+usual care	①②	5 times/Week	12	Breast cancer	Taxane
Kleckner et al. (25)	USA	170/185	55.6 \pm 11.8	55.9 \pm 9.7	12.1 \pm 60.9	5.7 \pm 10.0	Strength training	Chemotherapy	①③	60 min, qd	6	Breast/Lymphoma/Colon/Lung cancer	Taxane-, platinum-, or vinca alkaloid
Ikio et al. (24)	Japan	19/20	69(60–89)	64(57–87)	5(2–111)	6(2–93)	Strength training	Chemotherapy	①③	30 min, tiw	NA	Hematological malignancy/Gastrointestinal cancer	Vinca alkaloids, taxanes, platinum compounds and proteasome inhibitors
Gui et al. (23)	China	51/28	50 \pm 8	52 \pm 7	12(23.5)	6(21.4)	Sensory exercise	Chemotherapy	②③④	qd	2	Digestive malignancies	Oxaliplatin
Bao et al. (21)	USA	21/20	60.0(35.5, 77.9)	62.3(42.4, 79.0)	3.1 (0.5, 10.4)	3.7 (0.9, 15.3)	Yoga	Chemotherapy+usual care	①③④	60 min, qd	8	Breast/Uterine/Ovarian cancer	Taxane-, platinum-, or vinca alkaloid
Dhawan et al. (22)	India	22/23	50.5 \pm 7.9	52.5 \pm 6.6	10.2 \pm 7.8	9.8 \pm 8.6	Strength training	Chemotherapy	①③④	30 min, qd	10	Ovarian/Cervical/Lung cancer	Paclitaxel, carboplatin
Müller et al. (27)	Germany	49, 57/57	51.7 \pm 10.8/53.4 \pm 11.7	54.5 \pm 11.9	22.0 \pm 9.3/23.5 \pm 8.9	23.0 \pm 9.4	Sensory exercise/Strength training	Chemotherapy	①	35 min, tiw	NA	NA	Taxanes, platinum derivatives, vinca alkaloids
Schwenk et al. (28)	USA	11/11	68.73 \pm 8.72	71.82 \pm 8.85	49.91 \pm 44.11	44.63 \pm 56.78	Balance exercise	Chemotherapy+health education	④	45 min, biw	4	NA	NA
Vollmers et al. (31)	Germany	17/19	48.56 \pm 11.94	52.39 \pm 10.14	12	12	Sensory exercise	Chemotherapy+health education	④	60 min, biw	12	Breast cancer	Taxane
Zimmer et al. (33)	Germany	17/13	68.53(50–81)	70.00(50–81)	27.94 \pm 24.557	24.38 \pm 19.692	Strength training+balance exercise	Chemotherapy+health education	②③④	60 min, biw	8	Colon cancer	Bevacizumab, regorafenib, trastuzumab
Huang et al. (26)	China	32/34	54.56 \pm 9.4	57.65 \pm 9.8	4.66 \pm 1.10	4.79 \pm 1.06	Aerobic exercise	Chemotherapy+usual care	①②③	30 min, biw	6	Ovarian cancer	Taxane-, platinum-, or vinca alkaloid
Peng et al. (32)	China	23/23	53.17 \pm 9.29	52.15 \pm 7.25	NA	NA	Balance exercise	Chemotherapy+usual care	①②③④	15–30 min, tiw	12	Breast/Lymphoma cancer/Myeloma	Taxanes, platinum, vincristine, bortezomib, thalidomide
Visovsky et al. (30)	USA	19/19	48.8(24–65)	48.8(24–65)	NA	NA	Aerobic exercise+strength training	Chemotherapy+health education	①②④	30 min/time, 5–7 times/Week	12	Breast cancer	Taxane
Streckmann et al. (34)	Germany	28/28	44(20–67)	48(19–73)	NA	NA	Aerobic exercise+strength training	Chemotherapy	③④	biw	36	Lymphoma cancer	Taxanes,platinum, vincristine, bortezomib, thalidomide
Andersen et al. (20)	Canada	22/26	56.3 \pm 9.9	53 \pm 10.3	NA	NA	Stretching exercise	Chemotherapy+usual care	①	Four times a week	6	Breast cancer	Taxane

T, trial group; C, control group; NA, not reported; ① symptom score (total symptom score, numbness, and tingling); ② quality of life score (total score, physical, functional, social, emotional, and neurotoxicity); ③ pain; ④ balance; ⑤ functional assessment of neurotoxicity (FACT/GOG-NTX); qd, once a day; biw, 2 times/week; tiw, 3 times/week.



of generation (random number table or opaque sealed envelope drawing) with a low risk of bias (14, 20–22, 24, 26–30, 32, 33). Three trials did not clearly describe the method of randomization (23, 25, 31). Because of the particularities of the interventions, none study mentioned blinding of patients. Four trials (20, 25, 28, 32) reported allocation concealment. Blinding of outcome assessment was reported in four trials. None of the studies outcomes were incomplete and the risk of bias was low. None of the studies were selectively reported, and other bias were unclear (Figure 2; Supplementary Figure 1).

3.3 Main outcome

3.3.1 Symptom score

① Total symptom score Seven studies (20–22, 26, 27, 30, 32) reported total symptom scores in the test and control groups. Meta-analysis showed that the total symptom score of the test group was significantly lower than that of the control group (SMD: -0.62 ; 95% CI: $-0.99, -0.24$; $I^2=71.6\%$, Figure 3A). The results showed high heterogeneity, so we performed sensitivity analysis

(Supplementary Figure 2) and subgroup meta-analysis to analyze the source of heterogeneity. Sensitivity analysis showed that the included trials (20, 22) had a more significant impact on the results. The remaining studies made a meta-analysis, and the new result showed that the total symptom score of the test group was significantly lower than that of the control group (SMD: -0.31 ; 95% CI: $-0.53, -0.09$; $I^2=0.0\%$, Figure 3B).

② Numbness Five studies (21, 25, 27, 29, 32) reported numbness in the test and control groups, four studies (21, 25, 27, 29) reported numbness in the hands and feet, and one study (32) only reported numbness in the feet. Meta-analysis showed that the numbness of hands and feet in the test group was significantly lower than that in the control group (SMD: -0.19 ; 95% CI: $-0.35, -0.03$; $I^2=0.0\%$), and foot numbness was significantly lower in the test group than in the control group (SMD: -0.19 ; 95% CI: $-0.35, -0.03$; $I^2=0.0\%$).

③ Tingling Five studies (21, 24, 25, 27, 29) reported tingling in the test and control groups, three studies (21, 25, 29) reported tingling in




FIGURE 2 Risk of bias assessment in studies.




FIGURE 3 Forest plot. (A) Total symptom score. (B) Total symptom score after excluding two trail.

the hands and feet, one study (24) only reported tingling in the hands, and one study (11) only reported tingling in the feet. Meta-analysis showed that the tingling of hands and feet in the test group was significantly lower than that in the control group (SMD: -0.27; 95% CI: -0.39, -0.15; I²=0.2%, Figure 5). Among them, the hand tingling in the test group was significantly lower than that in the control group (SMD: -0.25; 95% CI: -0.43, -0.07; I²=0.0%), and the foot tingling sensation in the test group was significantly lower than that in the control group (SMD: -0.28; 95% CI: -0.45, -0.12; I²=45.9%).

3.3.2 Quality of life score

① Total quality of life score Five studies (14, 22, 26, 30, 32) reported the total quality of life score in the test and control groups. Meta-analysis showed that the quality of life score of the test group was significantly higher than that of the control group (SMD: 0.67; 95% CI: 0.41, 0.94; I²=32.3%, Figure 6).

② Physical, functional, social, emotional and neurotoxicity studies (24, 26, 33) reported the physical of the test group and the control group, Meta-analysis showed that the physical of the test group was significantly higher than that of the control group (SMD: 1.04; 95% CI: 0.65, 1.43; I²=82.4%); three studies (22, 24, 33) reported the functional of the test

group and the control group, and Meta-analysis showed that the functional of the test group was significantly higher than that of the control group (SMD: 0.83; 95% CI: 0.42, 1.25; I²=82.4%). The social, emotional, and neurotoxicity of the test group was not statistically significant compared with the control group (Figure 7).

3.3.3 Pain


Pain Seven studies (14, 21–23, 25, 26, 29, 32) reported pain in the test group and control group. Meta-analysis showed that the pain of the test group was significantly lower than that of the control group (SMD: -0.40; 95% CI: -0.62, -0.18; I²=0.0%, Figure 8A).

3.3.4 Balance

Balance Four studies (28, 30, 31, 33) reported balance in the test and control groups. Meta-analysis showed that the balance of the test group was significantly higher than that of the control group (SMD: 0.88; 95% CI: 0.50, 1.25; I²=0.0%, Figure 8B).

3.3.5 Fact/GOG-NTX

Four studies (21, 23, 31, 33) reported FACT/GOG-NTX in the test and control groups. Meta-analysis showed that FACT/GOG-NTX in



the test group was significantly lower than that in the control group (SMD: -0.68 ; 95% CI: $-0.99, -0.38$; $I^2 = 26.6\%$, Figure 9).

3.4 Subgroup meta-analysis

Total symptom score has high heterogeneity, so we did subgroup meta-analysis to find the source of heterogeneity (Supplementary Figure 3). We performed subgroup meta-analysis of CIPN with different disease duration (2.1 m 3 m 4.01 m 10 m). The subgroup meta-analysis showed that excluding the 2.1 m (20), 10 m (22), the combined results of 3 m and 4.01 m were less heterogeneous ($I^2 = 0.0\%$). Combined with sensitivity analyses, it suggests that the two studies may be the source of high heterogeneity, and that disease duration affects the difference in treatment outcome of exercise therapy.

3.5 Publication bias

Funnel plot of total symptom score (Figure 10) showed that there were two studies (20, 22) located outside the 95% CI, which may cause some publication bias. The reason for publication bias

may be that 1. Higher frequency of interventions in these two test group than other studies; 2. Small sample size may cause some publication bias.

3.6 Certainty assessment

The GRADE protocol was used to assess the certainty of the evidence (Supplementary Table 1). Accordingly, studies investigating the effect of total symptom score was regarded as very low quality, respectively, due to the moderate heterogeneity between studies and publication bias and risk of bias. The evidence for Physical, functional, social, emotional, neurotoxicity and were graded as low due to inconsistencies or imprecision.

4 Discussion

Exercise therapy, as a simple and feasible non-pharmacological intervention, has initially achieved results in the prevention and treatment of CIPN. However, the scattered nature of the evidence and the controversial nature of the efficacy create confusion in the choice of physicians and patients, so the exact efficacy of exercise in




FIGURE 5
Forest plot of tingling.

improving CIPN is a question that deserves further exploration. Based on the results of 15 randomized controlled trials, this paper analyzes the peripheral neuropathy caused by exercise therapy after chemotherapy. Meta-analysis shows that the use of exercise therapy in CIPN patients is effective in reducing their own numbness, pain, improving the quality of life, reducing pain and improving balance.

Among the 15 randomized controlled studies we included, there was some variation in the frequency and duration of each exercise session, with five studies (14, 26, 28, 31, 33) were twice a week, three studies (24, 27, 30) were three times a week, one study (20) was four times a week, one study (29) was five times a week, four studies (21–23, 25) were once a day and one study (32) was once every other day.

The majority of each session lasted around 30–60 min. Although the frequency of intervention varied in each study, we found that the individualized training programs adopted in each of these studies, which were tailored to the different physical conditions of the patients, confirmed that exercise was effective in reducing the symptoms of treatment-induced neuropathy, while there was no increase in the severity of neuropathy symptoms after the exercise intervention. Of the studies we included, all were combined exercises, except for TingBao (21), peng (32), and Elizabeth (20) where the interventions were yoga and balance training alone, and neuro gliding. In addition to this, we found that receiving more

physical activity and greater muscle bulk during exercise was also more likely to reduce the symptoms of CIPN. The exception to this is the elderly, who because of their specific abilities, have an increased fear of physical injury and falls due to excessive exercise, so the results of the Michael (28) study, which discussed a specific training program for the elderly, suggest that providing an adequate dose of exercise to elderly patients can also significantly reduce the symptoms of CIPN and reduce the risk of injury from falls. All of the exercise interventions studied were performed after chemotherapy, although the frequency and severity of CIPN subsided gradually with the cessation of chemotherapy. However, all patients showed varying degrees of remission after exercise. Also, the result of meta-analysis showed that exercise in the test group reduced the symptoms and severity of CIPN compared to the control group.

The human nervous system is divided into the central nervous system and peripheral nervous system. Because the central nervous system has the protection of blood–brain barrier, chemotherapeutic drugs are not easy to enter, on the contrary, the peripheral nervous system lacks the corresponding protection, so chemotherapeutic drugs easily enter and destroy the peripheral nerve cells. CIPN symptoms are caused precisely by the action of certain chemotherapy drugs on the body's peripheral nerves, causing




FIGURE 6
Forest plot of quality of life score.

patients to experience damage to sensory, motor and autonomic nerves. Pain receptor sensitization is an abnormal lesion of sensory nerves, and excessive release of inflammatory factors can lead to receptor sensitization, and chemotherapeutic drugs have been reported to up-regulate serum inflammatory factor levels (35) (IL-6, IL-8, IL-1P, TNF- α) in patients, thereby aggravating the severity of symptoms in patients. Exercise can reduce inflammation and oxidative stress in the body (36) by promoting the release of anti-inflammatory cytokines (37) and reducing oxidative markers (38), which can lead to diminished sensory symptoms. Meanwhile, the imbalance between neuronal apoptosis and the metabolic capacity of the nervous system is an important condition for the development of CIPN, and platinum-based compounds can damage the dorsal root ganglia (39), destroy the structure of DNA, and induce neuronal apoptosis (40). While exercise increases neuronal metabolism (40) and promotes secretion (41) of nerve growth factor, neurotrophins, etc., It is through this mechanism that damaged nerve fibers are regenerated and peripheral nervous system plasticity (42) is increased to achieve symptom relief in the balance training we incorporate.

In the studies we included, it can be shown that exercise therapy can improve the symptoms of CIPN. In a multi-center Randomized controlled trial, 170 cancer patients with CIPN were treated with moderate intensity exercise therapy for six weeks, and the symptoms of CIPN such as numbness of hands and feet, burning sensation were significantly alleviated. Duregon's systematic review of 5 RCTs also confirmed the effectiveness of exercise therapy in preventing

and improving CIPN. Our findings fit with the Lin et al. (43) which included five studies examining the effects of different exercise programs (general physical activity, Tai Chi, dance, yoga, and Pilates), all of which affirmed the effectiveness of exercise therapy interventions for CIPN, but the strength of this paper lies in the inclusion of more studies and the systematic dissection of CIPN symptoms, quality of life, and sense of balance. Further evidence of the supportive nature of exercise therapy interventions for CIPN.

The imbalance between neuronal apoptosis and the metabolic capacity of the nervous system is an important condition for the development of CIPN, and platinum-based compounds can damage the dorsal root ganglia (39), destroy the structure of DNA, and induce neuronal apoptosis (40). While exercise increases neuronal metabolism (40) and promotes secretion (41) of nerve growth factor, neurotrophins, etc., It is through this mechanism that damaged nerve fibers are regenerated and peripheral nervous system plasticity (42) is increased to achieve symptom relief in the balance training we incorporate. In an animal study (44), studies mimicking traumatic peripheral nerve injury in humans and mice have shown that exercise relieves neuropathy through various neurophysiological mechanisms in the peripheral nervous system, central nervous system. CIPN can affect the psychological status of cancer patients (45), aggravate anxiety and depression (46) and other adverse emotions, exercise can stimulate the brain to produce endorphin (47), regulate hormone levels (48), so that exercise can obtain a pleasant and comfortable experience. This reduces the psychological burden. In the studies we included, the interventions




FIGURE 7 Forest plot of physical, functional, social, emotional, and neurotoxicity.

were delivered through long cycles of exercise, which consistently enhanced muscle oxygenation (49), improving the body's activity endurance, enhancing its physical status and reducing pain, thus reducing the impact of CIPN on patients' daily activities and consequently improving their quality of life.

In addition, social, emotional, and neurotoxicity in quality of life were not statistically significant in this meta-analysis. The reason for this analysis may be due to insufficient statistics included, but combining the results of other clinical studies, exercise therapy intervention can significantly improve the social, emotional and neurotoxicity in the quality of life of patients, which is also consistent with a large number of exercise oncology studies (50).

Third, cancer patients with CIPN mostly experience motor and sensory disturbance symptoms such as lower limb dysesthesia and fatigue, while sensory disturbance makes the sensory system unable

to provide information to control cutaneous sensory nerve receptors (34), resulting in the inability of the human body to complete precise movements, and these abnormalities can affect the patient's balance function and increase the risk of falls. Intervention all through exercise induces neurons, muscles, and metabolic systems (34) of some adaptive processes, resulting in better stimulated postural control (51, 52), enhancing vestibular organ stability (53), and improving body balance. Our findings fit with the Lin et al. (43), which included five studies examining the effects of different exercise programs (general physical activity, Tai Chi, dance, yoga, and Pilates), all of which affirmed the effectiveness of exercise therapy interventions for CIPN, but the strength of this paper lies in the inclusion of more studies and the systematic dissection of CIPN symptoms, quality of life, and sense of balance. Further evidence of the supportive nature of exercise therapy interventions for CIPN.




FIGURE 8 Forest plot. (A) Pain. (B) Balance.




FIGURE 9 Forest plot of FACT/GOG-NTX.

The limitations of this study are: 1. the duration and frequency of treatment are different every week, and there are differences between onset and start of treatment; 2. there is a lack of reporting in adverse reactions in the included studies; 3. due to the non-uniform diagnostic criteria for CIPN, there may be some bias in the results.

In conclusion, exercise therapy can be effective in treating CIPN by improving symptom score (total symptom score, numbness, tingling), quality of life score (total score, physical function), pain, balance, and FACT/GOG-NTX questionnaires. The findings are consistent with the current results (14, 20–33) on this subject, but the most appropriate exercise therapy for each age




FIGURE 10
Funnel plot of the total symptom score.

group of patients can be refined in the future, and the findings of this study still need to be refined and validated by more high-quality, multicenter, large-sample RCTs in the future to further explore the application of exercise therapy in patients with CIPN and its long-term effects.

Author contributions

YH: conceptualization. YH, ML, and JX: acquisition of data. YH and TT: analysis and/or interpretation of data. YH, TT, and LL: drafting the manuscript. ML and JX: revising the manuscript critically for important intellectual content and supervision. YH, TT, ZY, YD and GL: data validation. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by Guangdong Province Science and Technology Innovation Strategy Special Fund (grant no: pdjh2021b0121).

References

- Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. *Chin. Med. J.* (2021) 134:783–91. doi: 10.1097/CM9.0000000000001474
- Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in survivors of adult cancers: ASCO guideline update. *J. Clin. Oncol.* (2020) 38:3325–48. doi: 10.1200/JCO.20.01399
- Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. *Pain.* (2014) 155:2461–70. doi: 10.1016/j.pain.2014.09.020
- Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. *Ann. Neurol.* (2017) 81:772–81. doi: 10.1002/ana.24951
- Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: a review. *Semin. Oncol.* (2021) 48:193–207. doi: 10.1053/j.seminoncol.2021.09.004
- Zajackowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. *Int. J. Mol. Sci.* (2019) 20:1451–1480. doi: 10.3390/ijms20061451
- Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. *Pain.* (2002) 98:195–203. doi: 10.1016/S0304-3959(02)00047-7
- Kautio AL, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. *J. Pain Symptom Manag.* (2008) 35:31–9. doi: 10.1016/j.jpainsymman.2007.02.043

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2023.1252259/full#supplementary-material>

9. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevic DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). *Cancer*. (2007) 110:2110–8. doi: 10.1002/cncr.23008
10. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. *JAMA*. (2013) 309:1359–67. doi: 10.1001/jama.2013.2813
11. Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. *Curr. Neuropharmacol.* (2019) 17:184–96. doi: 10.2174/1570159X15666170915143217
12. Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. *Ann Oncol: Official J European Society for Med Oncol.* (2020) 31:1306–19. doi: 10.1016/j.annonc.2020.07.003
13. Duregon F, Vendramin B, Bullo V, Gobbo S, Cugusi L, di Blasio A, et al. Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: a systematic review. *Crit. Rev. Oncol. Hematol.* (2018) 121:90–100. doi: 10.1016/j.critrevonc.2017.11.002
14. Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. *Ann Oncol: Official J European Society for Med Oncol.* (2014) 25:493–9. doi: 10.1093/annonc/mdt568
15. Park JS, Höke A. Treadmill exercise induced functional recovery after peripheral nerve repair is associated with increased levels of neurotrophic factors. *PLoS One.* (2014) 9:e90245. doi: 10.1371/journal.pone.0090245
16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev.* (2021) 10:89. doi: 10.1186/s13643-021-01626-4
17. GRAD. *Epro guideline development tool*. Canada: McMaster University (2015).
18. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *J. Clin. Epidemiol.* (2011) 64:401–6. doi: 10.1016/j.jclinepi.2010.07.015
19. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ (Clinical Res).* (2008) 336:924–6. doi: 10.1136/bmj.39489.470347.AD
20. Andersen Hammond E, Pitz M, Steinfeld K, Lambert P, Shay B. An exploratory randomized trial of physical therapy for the treatment of chemotherapy-induced peripheral neuropathy. *Neurorehabil. Neural Repair.* (2020) 34:235–46. doi: 10.1177/1545968319899918
21. Bao T, Zhi I, Baser R, Hooper M, Chen C, Piulson L, et al. Yoga for chemotherapy-induced peripheral neuropathy and fall risk: a randomized controlled trial. *JNCI Cancer Spectrum.* (2020) 4:pkaa048. doi: 10.1093/jncics/pkaa048
22. Dhawan S, Andrews R, Kumar L, Wadhwa S, Shukla G. A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among Cancer patients. *Cancer Nurs.* (2020) 43:269–80. doi: 10.1097/NCC.0000000000000693
23. Gui Q, Li D, Zhuge Y, Xu C. Efficacy of exercise rehabilitation program in relieving Oxaliplatin induced peripheral neurotoxicity. *Asian Pac. J. Cancer Prev.* (2021) 22:705–9. doi: 10.31557/APJCP.2021.22.3.705
24. Ikio Y, Sagari A, Nakashima A, Matsuda D, Sawai T, Higashi T. Efficacy of combined hand exercise intervention in patients with chemotherapy-induced peripheral neuropathy: a pilot randomized controlled trial. *Supportive care in cancer: Official J Multinat Assoc Supportive Care in Cancer.* (2022) 30:4981–92. doi: 10.1007/s00520-022-06846-5
25. Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. *Supportive care in cancer: Official J Multinat Assoc Supportive Care in Cancer.* (2018) 26:1019–28. doi: 10.1007/s00520-017-4013-0
26. Mengqiu H. (2019). Investigation on the current situation of peripheral neuropathy caused by chemotherapy in patients with gynecological malignant tumor and study on the intervention effect of exercise therapy. Master's Thesis, Tianjin Medical University.
27. Müller J, Weiler M, Schneeweiss A, Haag GM, Steindorf K, Wick W, et al. Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial. *Br. J. Cancer.* (2021) 125:955–65. doi: 10.1038/s41416-021-01471-1
28. Schwenk M, Grewal GS, Holloway D, Muchna A, Garland L, Najafi B. Interactive sensor-based balance training in older Cancer patients with chemotherapy-induced peripheral neuropathy: a randomized controlled trial. *Gerontology.* (2016) 62:553–63. doi: 10.1159/000442253
29. Şimşek NY, Demir A. Cold application and exercise on development of peripheral neuropathy during Taxane chemotherapy in breast Cancer patients: a randomized controlled trial. *Asia Pac. J. Oncol. Nurs.* (2021) 8:255–68. doi: 10.4103/apjon.apjon-2075
30. Visovsky C, Bovaird JA, Tofthagen C, Rice J. Heading off peripheral neuropathy with exercise: the Hope study. *Экономика по-воприраде.* (2014) 2:115–21. doi: 10.13189/nh.2014.020602
31. Vollmers PL, Mundhenke C, Maass N, Bauerschlag D, Kratzstein S, Röcken C, et al. Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy. *J. Cancer Res. Clin. Oncol.* (2018) 144:1785–92. doi: 10.1007/s00432-018-2686-5
32. Yuxiao P. (2019). Effect of balance training on patients with chemotherapy-induced peripheral neuropathy. Hebei Medical University. Available at: <https://kns.cnki.net/KCMS/detail/detail.aspx?dbname=CMFD202001&filename=1019629847.nh>.
33. Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. *Supportive care in cancer: Official J Multinat Assoc Supportive Care in Cancer.* (2018) 26:615–24. doi: 10.1007/s00520-017-3875-5
34. Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, et al. Exercise intervention studies in patients with peripheral neuropathy: A systematic review. *Sports Med.* (2014) 44:1289–304. doi: 10.1007/s40279-014-0207-5
35. Makker PG, Duffy SS, Lees JG, Perera CJ, Tonkin RS, Butovsky O, et al. Characterisation of immune and Neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. *PLoS One.* (2017) 12:e0170814. doi: 10.1371/journal.pone.0170814
36. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. *Nat. Rev. Immunol.* (2011) 11:607–15. doi: 10.1038/nri3041
37. Arazi H, Eghbali E, Suzuki K. Creatine supplementation, physical exercise and oxidative stress markers: a review of the mechanisms and effectiveness. *Nutrients.* (2021) 13:869–885. doi: 10.3390/nu13030869
38. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. *Neurobiol. Dis.* (2002) 9:220–33. doi: 10.1006/nbdi.2001.0468
39. Stojanovska V, McQuade R, Rybalka E, Nurgali K. Neurotoxicity associated with platinum-based anti-Cancer agents: what are the implications of copper transporters? *Curr. Med. Chem.* (2017) 24:1520–36. doi: 10.2174/0929867324666170112095428
40. Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. *J. Pain.* (2012) 13:276–84. doi: 10.1016/j.jpain.2011.11.009
41. Niu Y. Aerobic exercise improves VCI through circRIMS2/miR-186/BDNF-mediated neuronal apoptosis. *Mol. Med.* (2021) 27:4.
42. Taube W, Gruber M, Gollhofer A. Spinal and supraspinal adaptations associated with balance training and their functional relevance. *Acta Physiol (Oxford).* (2008) 193:101–16. doi: 10.1111/j.1748-1716.2008.01850.x
43. Lin WL, Wang RH, Chou FH, Feng JJ, Fang CJ, Wang HH. The effects of exercise on chemotherapy-induced peripheral neuropathy symptoms in cancer patients: a systematic review and meta-analysis. *Supportive care in cancer: Official J Multinat Assoc Supportive Care in Cancer.* (2021) 29:5303–11. doi: 10.1007/s00520-021-06082-3
44. Park JS, Kim S, Hoke A. An exercise regimen prevents development paclitaxel induced peripheral neuropathy in a mouse model. *J Peripheral Nervous Syst: JPNS.* (2015) 20:7–14. doi: 10.1111/jns.12109
45. Yue W. (2017). Relevant study on the evaluation of chemotherapy-induced peripheral neuropathy in cancer patients. Page 122. Available at: https://kns.cnki.net/kcms2/article/abstract?v=5faiAHckh4ykvZJM2u6u0GbVBPbLb6-2dOaTwXDEUHR-X94aHV7rSGZvqxeNSqCLQcGIW9dtMpDvVgZC_ca4AEvo18RznedwJ3UPEAH15QzZFNezsmZirg==&uniplatform=NZKPT&language=CHS.
46. Tian J, Chen GL, Zhang HR. Sleep status of cervical cancer patients and predictors of poor sleep quality during adjuvant therapy. *Supportive care in cancer: Official J Multinat Assoc Supportive Care in Cancer.* (2015) 23:1401–8. doi: 10.1007/s00520-014-2493-8
47. Al Jadaan SA, Al Rabeeah A. Mesenteric fibromatosis: case report and literature review. *J. Pediatr. Surg.* (1999) 34:1130–2. doi: 10.1016/S0022-3468(99)90583-3
48. Candanedo-González F, Luna-Pérez P. Cystic lymphangioma of the mesentery. Clinical, radiological, and morphological analysis. *Rev. Gastroenterol. Mex.* (2000) 65:6–10.
49. Trangmar SJ, González-Alonso J. Heat, hydration and the human brain, heart and skeletal muscles. *Sports Med.* (2019) 49:69–85. doi: 10.1007/s40279-018-1033-y
50. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise guidelines for Cancer survivors: consensus statement from international multidisciplinary roundtable. *Med. Sci. Sports Exerc.* (2019) 51:2375–90. doi: 10.1249/MSS.0000000000002116
51. Granacher U, Gollhofer A, Hortobágyi T, Kressig RW, Muehlbauer T. The importance of trunk muscle strength for balance, functional performance, and fall prevention in seniors: a systematic review. *Sports Med.* (2013) 43:627–41. doi: 10.1007/s40279-013-0041-1
52. Zech A, Hübscher M, Vogt L, Banzer W, Hänsel F, Pfeifer K. Balance training for neuromuscular control and performance enhancement: a systematic review. *J. Athl. Train.* (2010) 45:392–403. doi: 10.4085/1062-6050-45.4.392
53. Moran RN, Murray NG, Escó MR, Dobbs W, McAllister-Deitrick J. Effects of exercise on symptoms, vestibular/ocular motor screening and postural stability in a college-aged sample. *Concussion (London, England).* (2020) 5:CNC73. doi: 10.2217/cnc-2020-0003